A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

BACKGROUND: Mirikizumab (miri), an anti-IL23/p19 monoclonal antibody, demonstrated efficacy compared with placebo (PBO) in the Phase 3, multicentre, randomized, double-blind LUCENT-1 induction study in patients with moderately to severely active ulcerative colitis (UC, NCT03518086). PURPOSE: This an...

Descripción completa

Detalles Bibliográficos
Autores principales: Danese, S, Dignass, A, Matsuoka, K, Ferrante, M, Long, M, Redondo, I, Gibble, T H, Moses, R, Morris, N, Li, X, Milch, C, Abreu, M, Jones, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991172/
http://dx.doi.org/10.1093/jcag/gwac036.184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991172/
http://dx.doi.org/10.1093/jcag/gwac036.184

Ejemplares similares